NCT05076877View on ClinicalTrials.gov

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

February 10, 2022

Study Completion Date

February 10, 2022

Conditions
Healthy
Interventions
DRUG

Lazertinib

Lazertinib tablets will be administered orally, alone or in combination with probe substrates.

DRUG

Midazolam

Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.

DRUG

Rosuvastatin

Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.

DRUG

Metformin

Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.

Trial Locations (1)

84124

PRA Health Sciences, Salt Lake City

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT05076877 - A Study of Lazertinib (JNJ-73841937) in Healthy Participants | Biotech Hunter | Biotech Hunter